174 related articles for article (PubMed ID: 34996489)
1. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.
Jiang J; Ren Y; Xu C; Lin X
Diagn Pathol; 2022 Jan; 17(1):4. PubMed ID: 34996489
[TBL] [Abstract][Full Text] [Related]
2. Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report.
Chai P; Zhou C; Jia R; Wang Y
Diagn Pathol; 2020 Jan; 15(1):2. PubMed ID: 31900183
[TBL] [Abstract][Full Text] [Related]
3. Brain radiotherapy and anlotinib control primary cardiac angiosarcoma with metastases: A case report.
Ma YY; Li ZK; Liao ZY; Peng Y; Zeng L; Ma DY
Medicine (Baltimore); 2024 Apr; 103(17):e37914. PubMed ID: 38669418
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
[TBL] [Abstract][Full Text] [Related]
5. NUT midline carcinoma mimicking a germ cell tumor: a case report.
Harada Y; Koyama T; Takeuchi K; Shoji K; Hoshi K; Oyama Y
BMC Cancer; 2016 Nov; 16(1):895. PubMed ID: 27855672
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
7. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
9. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin.
Tanaka M; Kato K; Gomi K; Yoshida M; Niwa T; Aida N; Kigasawa H; Ohama Y; Tanaka Y
Am J Surg Pathol; 2012 Mar; 36(3):381-8. PubMed ID: 22301500
[TBL] [Abstract][Full Text] [Related]
10. [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].
Hao H; Zhang M; Zhang G; Zhu H; Bao W
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):60-64. PubMed ID: 31948540
[TBL] [Abstract][Full Text] [Related]
11. [A Case Report of Primary Pulmonary NUT Carcinoma and Literature Review].
Liu X; Li Y; Yu M; Zhou L
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):63-68. PubMed ID: 33478193
[TBL] [Abstract][Full Text] [Related]
12. Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S; Li H; Lin Y; Xie Y; Yin Z; Ge W; Yu T
Anticancer Drugs; 2022 Jan; 33(1):e548-e554. PubMed ID: 34321419
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
[TBL] [Abstract][Full Text] [Related]
14. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
15. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
16. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.
Xie XH; Wang LQ; Qin YY; Lin XQ; Xie ZH; Liu M; Zhang JX; Ouyang M; Liu J; Gu YY; Li SY; Zhou CZ
Orphanet J Rare Dis; 2020 Jul; 15(1):183. PubMed ID: 32650830
[TBL] [Abstract][Full Text] [Related]
17. [A case report of anlotinib treatment of an advanced lung squamous cell cancer patients without driver gene mutations].
Liu YH; Zhang YW; Li JS; Dai XM
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):447-448. PubMed ID: 31216831
[No Abstract] [Full Text] [Related]
18. In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.
Guo L; Zhang L; Guan Y; Li Y; Zhang C; Guo Q
Thorac Cancer; 2021 Mar; 12(5):593-602. PubMed ID: 33438349
[TBL] [Abstract][Full Text] [Related]
19. NUT midline carcinoma in the right orbit: a case report.
Ding T; Wang Y; Zhao T; Xu Z; Gao W; Cui Z; Du Y
Cancer Biol Ther; 2019; 20(8):1091-1096. PubMed ID: 30991882
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Analysis of Five Cases of NUT Midline Carcinoma, including One with the Gingiva.
Zhou L; Yong X; Zhou J; Xu J; Wang C
Biomed Res Int; 2020; 2020():9791208. PubMed ID: 32149149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
